Gan & Lee’s Ondibta Receives Positive CHMP Opinion – EU Biosimilar Pathway Opened
Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced that the European Medicines Agency (EMA) has...
SHA: 603087
Gan & Lee Transfers MedTech Control to Hillhouse Investment, Accelerating Drug Delivery Innovation
Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has transferred its controlling stake...
Gan & Lee Pharma, Fiocruz Sign MoU to Advance GZR4 and GZR102 Insulin Candidates
Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has signed a Memorandum of...
Gan & Lee Secures 3 B RMB Supply Deal for Insulin Glargine in Brazil’s National PDP
Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced a landmark Technology Transfer and Supply...
Gan & Lee Pharmaceuticals Presents Phase II Results of GZR18 and GZR4 at ADA Scientific Sessions
China-based Gan & Lee Pharmaceuticals (SHA: 603087) presented multiple Phase II clinical outcomes for its...
Gan & Lee Pharmaceuticals Signs PDP Agreement with Brazilian Health Ministry
Gan & Lee Pharmaceuticals (SHA: 603087) announced the signing of Parcerias para o Desenvolvimento Produtivo...
Gan & Lee Pharmaceuticals Reports 417 Million USD Revenue and 80.75% Profit Surge in 2024
Gan & Lee Pharmaceuticals (SHA: 603087) reported revenues of RMB 3.045 billion (USD 417 million)...
Gan & Lee’s GZR102 Receives NMPA Clinical Trial Clearance for Type 2 Diabetes
China’s Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial clearance...
Gan & Lee Pharmaceuticals Secures Pakistan Approval for Insulin Glargine Cartridge
Gan & Lee Pharmaceuticals (SHA: 603087) has announced the receipt of marketing approval for its...
Gan & Lee Pharmaceuticals Joins Brazil’s PDP for Localized Insulin Production
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced receiving a financial pledge of BRL130 million...
Gan & Lee Pharmaceuticals Doses First Patient in GZR4 Phase III Study for Diabetes
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Gan & Lee’s GZR18 Shows Significant Weight Loss in Phase IIb Study at ObesityWeek 2024
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the oral presentation...
Gan & Lee Pharmaceuticals Initiates Phase I Clinical Trial for Biosimilar Secukinumab
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the commencement of...
Gan & Lee Pharmaceuticals Gets FDA Green Light for Phase I Clinical Trial of Insulin Aspart Biosimilar
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company based in China, has received...
Gan & Lee Pharmaceuticals Gains Market Foothold in Algeria with Insulin Product Approvals
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company, has announced that it has...
Gan & Lee Pharmaceuticals’ GZR18 Outperforms Market Similars in Weight Reduction Study
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the presentation of...
Gan & Lee Pharmaceuticals Gains Marketing Approval for Insulin Glargine in Mexico
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...
Gan & Lee Pharmaceuticals Reports 52.31% YOY Revenue Growth in 2023, Driven by Insulin Sales
Gan & Lee Pharmaceuticals (SHA: 603087) has announced its financial results for 2023, reporting a...
Gan & Lee Pharmaceuticals Commences Clinical Trial for Innovative GLP-1 Agonist GZR18
Gan & Lee Pharmaceuticals (SHA: 603087), a leading Chinese pharmaceutical company, has announced the commencement...
Gan & Lee Pharmaceuticals Receives Bolivian Approval for Insulin Aspart, Expanding Access to Rapid-Acting Insulin
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...